Gainers Aardvark Therapeutics (NASDAQ:AARD) shares increased by 8.5% to $6.28 during Friday's a

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) shares crossed above its 50 day moving

The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical c

The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical c

Xtandi (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic

Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) shares passed below its 200-day moving

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday'

Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confir

Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confir

Galmed Pharmaceuticals (NASDAQ: GLMD - Get Free Report) is expected to issue its results before the

Crown Holdings Inc (CCK) stock gained 16.4% in pre-market trading after reporting strong Q2 results

Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 25.1% to $3.79 during Monday&

Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticl

Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticl

Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-mark

Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 40.9% to $0.16 during Thursday's pre-

Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T

https://x.com/PatentGrants/status/2072409116040130916 https://patentcenter.uspto.gov/applications/17

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m

Colospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd. ("Galmed") (NASDAQ:G

Colospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. ("Galmed") (NASDAQ:GLMD) today announced that it has entered int

Transaction will add FDA Breakthrough Device-Designated technology with active U.S. pivotal IDE tria

https://www.gov.uk/government/news/resmetirom-rezdiffra-authorised-to-treat-metabolic-dysfunction-as

Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Com

- Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis

Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg

Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg

Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Com

Novel vascularized, sensor-embedded cardiac organoid model will focus on chronic post-MI remodeling

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) was the target of a large growth in sho

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-s

Recently, Galmed announced breakthrough medicinal chemistry work converting Aramchol into a brain-pe

Clearsign Technologies Corp (NASDAQ: CLIR) shares rose 11.3% in pre-market trading after reporting b

Galmed said it developed a new formulation of its SCD1 inhibitor, Aramchol, designed to cross the bl

Galmed Pharmaceuticals Ltd. shares are trading higher after it announced the development of a brain

98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood cir

TEL AVIV, Israel, March 31, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed

Surrozen (NASDAQ: SRZN - Get Free Report) and Galmed Pharmaceuticals (NASDAQ: GLMD - Get Free Report

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) was the recipient of a large decrease i

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-st

TEL AVIV, Israel, Jan. 30, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"